You searched for Amanda Cole

We found for

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Payment Models for Multi-Indication Therapies

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Indication-Based Pricing (IBP) Consultation Report

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates

Making Outcome-Based Payment a Reality in the NHS

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Barriers to Uptake of Minimal Access Surgery in the United Kingdom

Data Governance Arrangements for Real-World Evidence: South Korea

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Improving Efficiency and Resource Allocation in Future Cancer Care

Latest Research & Publications

All Publications

We found for

Filter results by

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

Payment Models for Multi-Indication Therapies

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Indication-Based Pricing (IBP) Consultation Report

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates

Making Outcome-Based Payment a Reality in the NHS

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Barriers to Uptake of Minimal Access Surgery in the United Kingdom

Data Governance Arrangements for Real-World Evidence: South Korea

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Improving Efficiency and Resource Allocation in Future Cancer Care